{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:35:57Z","timestamp":1788125757502,"version":"build-2803163510"},"reference-count":72,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013699","name":"Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100013699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R35CA197706"],"award-info":[{"award-number":["NIH R35CA197706"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second most common cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is only temporarily effective for advanced-stage PCa, as the disease inevitably progresses to castration-resistant prostate cancer (CRPC). The protein nucleolin (NCL) is overexpressed in several types of human tumors where it is also mislocalized to the cell surface. We previously reported the identification of a single-chain fragment variable (scFv) immuno-agent that is able to bind NCL on the surface of breast cancer cells and inhibit proliferation both in vitro and in vivo. In the present study, we evaluated whether NCL could be a valid therapeutic target for PCa, utilizing DU145, PC3 (CRPC), and LNCaP (androgen-sensitive) cell lines. First, we interrogated the publicly available databases and noted that higher NCL mRNA levels are associated with higher Gleason Scores as well as with recurrent and metastatic tumors. Then, using our anti-NCL scFv, we demonstrated that NCL is expressed on the surface of all three tested cell lines and that NCL inhibition results in reduced proliferation and migration. We also measured the inhibitory effect of NCL targeting on the biogenesis of oncogenic microRNAs such as miR-21, -221 and -222, which was cell context dependent. Taken together, our data provide evidence that NCL targeting inhibits the key hallmarks of malignancy in PCa cells and may provide a novel therapeutic option for patients with advanced-stage PCa.<\/jats:p>","DOI":"10.3390\/cancers12071861","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:45:31Z","timestamp":1594374331000},"page":"1861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4440-1477","authenticated-orcid":false,"given":"Tyler","family":"Sheetz","sequence":"first","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tessari","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pawlikowski","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Braddom","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha","family":"Posid","sequence":"additional","affiliation":[{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Zynger","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"James","sequence":"additional","affiliation":[{"name":"Mass Spectroscopy and Proteomics Facility, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-3862","authenticated-orcid":false,"given":"Valerio","family":"Embrione","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareesma","family":"Parbhoo","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-5765","authenticated-orcid":false,"given":"Claudia","family":"Foray","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"},{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with Newly Diagnosed Metastatic Prostate Cancer in the \u201cDocetaxel Era\u201d: Data from 917 Patients in the Control Arm of the STAMPEDE Trial ( MRC PR08, CRUK\/06\/019 )","volume":"67","author":"James","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: A systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/1008-682X.177121","article-title":"Genomic predictors for treatment of late stage prostate cancer","volume":"18","author":"Shevrin","year":"2016","journal-title":"Asian J. Androl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JME-11-0018","article-title":"Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target","volume":"47","author":"Shiota","year":"2011","journal-title":"J. Mol. Endocrinol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Dan","year":"2015","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e12589","DOI":"10.1111\/ecc.12589","article-title":"Factors associated with current and severe physical side-effects after prostate cancer treatment: What men report","volume":"27","author":"Steentjes","year":"2018","journal-title":"Eur. J. Cancer Care"},{"key":"ref_9","first-page":"S1","article-title":"Navigating the evolving therapeutic landscape in advanced prostate cancer","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrg3198","article-title":"MicroRNA profiling: Approaches and considerations","volume":"13","author":"Pritchard","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"50240","DOI":"10.18632\/oncotarget.16933","article-title":"Micrornas in prostate cancer: An overview","volume":"8","author":"Vanacore","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/pros.21246","article-title":"Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy","volume":"71","author":"Zhang","year":"2011","journal-title":"Prostate"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.juro.2011.11.082","article-title":"MiR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer","volume":"187","author":"Li","year":"2012","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2015.08.011","article-title":"Small Molecules Targeting MicroRNA for Cancer Therapy: Promises and Obstacles","volume":"219","author":"Wen","year":"2015","journal-title":"J Controll. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2052-8426-2-7","article-title":"microRNA therapies in cancer","volume":"2","author":"Rothschild","year":"2014","journal-title":"Mol. Cell Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-1033.1982.tb06989.x","article-title":"Detection and Localization of a Class of Proteins Immunologically Related to a 100-kDa Nucleolar Protein","volume":"128","author":"Bugler","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0092-8674(89)90241-9","article-title":"Major nucleolar proteins shuttle between nucleus and cytoplasm","volume":"56","author":"Borer","year":"1989","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcb.2006.11.010","article-title":"Nucleolin: A multiFACeTed protein","volume":"17","author":"Mongelard","year":"2007","journal-title":"Trends Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0955-0674(90)90137-4","article-title":"The nucleolus and ribosome formation","volume":"2","author":"Warner","year":"1990","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1096\/fasebj.13.14.1911","article-title":"Molecular dissection of nucleolin\u2019s role in growth and cell proliferation: New insights","volume":"13","author":"Srivastava","year":"1999","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.15537\/smj.2016.12.15972","article-title":"Roles of nucleolin: Focus on cancer and anti-cancer therapy","volume":"37","author":"Chen","year":"2016","journal-title":"Saudi Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/excr.2000.5071","article-title":"The Cell-Surface-Expressed Nucleolin Is Associated with the Actin Cytoskeleton","volume":"261","author":"Hovanessian","year":"2000","journal-title":"Exp. Cell Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1093\/nar\/gkr488","article-title":"Enhanced translation by Nucleolin via G-rich elements in coding and non-coding regions of target mRNAs","volume":"39","author":"Abdelmohsen","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4161\/rna.19718","article-title":"RNA-binding protein nucleolin in disease","volume":"9","author":"Abdelmohsen","year":"2012","journal-title":"RNA Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2006-08-043257","article-title":"Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA","volume":"109","author":"Otake","year":"2007","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fernandes, E., Freitas, R., Ferreira, D., Soares, J., Azevedo, R., Gaiteiro, C., Peixoto, A., Oliveira, S., Cotton, S., and Relvas-Santos, M. (2020). Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells. Cancers, 12.","DOI":"10.2139\/ssrn.3516117"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1101\/gad.14.10.1236","article-title":"Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation","volume":"14","author":"Chen","year":"2000","journal-title":"Genes Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.yexcr.2008.03.016","article-title":"Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells","volume":"314","author":"Akiyama","year":"2008","journal-title":"Exp. Cell Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1084\/jem.20120950","article-title":"In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation","volume":"210","author":"Pichiorri","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11010-013-1857-6","article-title":"A comparative study of glycoproteomes in androgen-sensitive and -independent prostate cancer cell lines","volume":"386","author":"Drabik","year":"2014","journal-title":"Mol. Cell Biochem."},{"key":"ref_34","first-page":"287","article-title":"MicroRNAs in Cancer","volume":"18","author":"Garofalo","year":"2014","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/aps.2010.48","article-title":"Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells","volume":"31","author":"Shi","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_36","first-page":"423","article-title":"Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel","volume":"19","year":"2015","journal-title":"Wspolczesna Onkol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/0008-5472.CAN-09-1448","article-title":"miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth","volume":"69","author":"Ribas","year":"2009","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1038\/onc.2013.374","article-title":"Androgen Receptor and MicroRNA-21 axis down-regulates transforming growth factor beta receptor II (TGFBR2) expression in Prostate Cancer","volume":"33","author":"Mishra","year":"2014","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/jca.11038","article-title":"Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer","volume":"6","author":"Leite","year":"2015","journal-title":"J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/pros.23187","article-title":"Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy","volume":"76","author":"Guan","year":"2016","journal-title":"Prostate"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23716","DOI":"10.1074\/jbc.M701805200","article-title":"miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1","volume":"282","author":"Galardi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/sj.emboj.7601790","article-title":"Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation","volume":"26","author":"Egan","year":"2007","journal-title":"EMBO J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.gene.2015.07.017","article-title":"Effects of microRNA-221\/222 on cell proliferation and apoptosis in prostate cancer cells","volume":"572","author":"Wang","year":"2015","journal-title":"Gene"},{"key":"ref_44","first-page":"517","article-title":"The role of microRNA in castration-resistant prostate cancer","volume":"32","author":"Thieu","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/onc.2013.230","article-title":"MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A","volume":"33","author":"Sun","year":"2014","journal-title":"Oncogene"},{"key":"ref_46","first-page":"617","article-title":"The role of microRNA-221 and -222 in Androgen-independent Prostate Cancer Cell lines","volume":"69","author":"Sun","year":"2010","journal-title":"Cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/1940-6207.CAPR-10-0167","article-title":"MicroRNAs 221\/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer","volume":"4","author":"Chen","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pros.22456","article-title":"The altered expression of MiR-221\/-222 and MiR-23b\/-27b is associated with the development of human castration resistant prostate cancer","volume":"72","author":"Sun","year":"2012","journal-title":"Prostate"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1073\/pnas.1507087112","article-title":"Human anti-nucleolin recombinant immunoagent for cancer therapy","volume":"112","author":"Palmieri","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clgc.2016.12.004","article-title":"Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells","volume":"15","author":"Chalfin","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1158\/0008-5472.CAN-10-0920","article-title":"A new paradigm for aptamer therapeutic AS1411 action: Uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism","volume":"70","author":"Teng","year":"2010","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/onc.2015.176","article-title":"A microRNA code for prostate cancer metastasis","volume":"35","author":"Bonci","year":"2016","journal-title":"Oncogene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2009.03.077","article-title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells","volume":"383","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00018-016-2176-3","article-title":"Dissecting the role of microRNAs in prostate cancer metastasis: Implications for the design of novel therapeutic approaches","volume":"73","author":"Doldi","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cancergen.2015.02.010","article-title":"Microdissecting the role of microRNAs in the pathogenesis of prostate cancer","volume":"208","author":"Ayub","year":"2015","journal-title":"Cancer Genet."},{"key":"ref_56","first-page":"1809","article-title":"LNCaP model of human prostatic carcinoma","volume":"43","author":"Horoszewicz","year":"1983","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/acsami.9b15803","article-title":"Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells","volume":"12","author":"Pesarrodona","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41388-018-0556-x","article-title":"Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation","volume":"38","author":"Xu","year":"2019","journal-title":"Oncogene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.7150\/jca.37776","article-title":"The nucleolin antagonist N6L inhibits LINE1 retrotransposon activity in non-small cell lung carcinoma cells","volume":"11","author":"Ramos","year":"2020","journal-title":"J. Cancer"},{"key":"ref_60","first-page":"1420","article-title":"Therapeutic applications of AS1411 aptamer, an update review","volume":"155","author":"Bayat","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/1061186X.2015.1009075","article-title":"Tumor targeting with a 99mTc-labeled AS1411 aptamer in prostate tumor cells","volume":"23","author":"Noaparast","year":"2015","journal-title":"J. Drug Target"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Russell, P.J., and Kingsley, E.A. (2003). Human Prostate Cancer Cell Lines. Methods Mol. Med. Prostate Cancer Methods Protoc., 21\u201339.","DOI":"10.1385\/1592593720"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-017-0067-7","article-title":"Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer article","volume":"9","author":"Wolfson","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bios.2016.04.091","article-title":"Aptamers, antibody scFv, and antibody Fab\u2019 fragments: An overview and comparison of three of the most versatile biosensor biorecognition elements","volume":"85","author":"Thompson","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"87016","DOI":"10.18632\/oncotarget.13522","article-title":"A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy","volume":"7","author":"Palmieri","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23314","DOI":"10.1038\/srep23314","article-title":"In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe","volume":"6","author":"Mazzocco","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/MNM.0000000000000698","article-title":"A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen","volume":"38","author":"Nawaz","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm. Stat."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Limame, R., Wouters, A., Pauwels, B., Fransen, E., Peeters, M., Lardon, F., De Wever, O., and Pauwels, P. (2012). Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046536"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/pros.20961","article-title":"Optimizing Molecular Signatures for Predicting Prostate Cancer Recurrence","volume":"69","author":"Sun","year":"2009","journal-title":"Prostate"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2004.05.158","article-title":"Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy","volume":"22","author":"Yu","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chandran, U.R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., Michalopoulos, G., Becich, M., and Monzon, F.A. (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-64"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:54Z","timestamp":1760176194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":72,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071861"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071861","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}